登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05883852,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 70 岁;性别:仅女性
登记记录的入选字段
Unilateral invasive carcinoma confirmed by histology (regardless of pathological type);
入选标准第 3 条
Early breast cancer, pathologically confirmed as HER2 positive; HER2 positive definition: Immunohistochemical HER2 3+ or FISH/CISH test positive (with amplification) is defined as HER2 positive;
入选标准第 5 条
Postoperative pathological stage pT1-4N1-3M0;
入选标准第 6 条
If any tumor >T4a (accompanied by skin invasion, mass adhesion fixation, inflammatory breast cancer);
排除标准第 4 条
The longest period from surgery to randomization was not more than 8 weeks, and no adjuvant therapy had been received after surgery;
入选标准第 8 条
Women of childbearing age refuse contraception during treatment and within 8 weeks after completion of treatment;
排除标准第 13 条
0-1 for ECOG;
入选标准第 2 条
The major organs function normally, that is, meet the following criteria: (1) The standard of blood routine examination shall meet: HB ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5×109 /L; PLT ≥100×109 /L; (2) Biochemical examination should meet the following standards: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3 x ULN; Serum Cr ≤1.5×ULN;
入选标准第 11 条
Patients with clinical or imaging suspicion of malignancy on the opposite breast but not confirmed, requiring biopsy;
排除标准第 5 条
Malignant neoplasms (other than basal cell carcinoma of the skin and carcinoma in situ of the cervix), including contralateral breast cancer, within the previous 5 years;
排除标准第 7 条
Pregnant and lactating women;
排除标准第 14 条
Those who tested positive for pregnancy before taking the drug after joining the trial;
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05883852,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Women aged 18-70; 0-1 for ECOG; Unilateral invasive carcinoma confirmed by histology (regardless of pathological type); No gross or microscopic tumor remains after surgical resection; Early breast cancer, pathologically confirmed as HER2 positive; HER2 positive definition: Immunohistochemical HER2 3+ or FISH/CISH test positive (with amplification) is defined as HER2 positive; Postoperative pathological stage pT1-4N1-3M0; Did not receive neoadjuvant chemotherapy in the past; The longest period from surgery to randomization was not more than 8 weeks, and no adjuvant therapy had been received after surgery; No peripheral neuropathy; Good postoperative recovery, at least 1 week interval between operation; The major organs function normally, that is, meet the following criteria: (1) The standard of blood routine examination shall meet: HB ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5×109 /L; PLT ≥100×109 /L; (2) Biochemical examination should meet the following standards: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3 x ULN; Serum Cr ≤1.5×ULN; Contraception during treatment for women of reproductive age; Cardiac function: LVEF>50% for ultrasound examination; The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up。排除标准:Exclusion Criteria:
Bilateral breast cancer or carcinoma in situ DCIS/LCIS; Have received chemotherapy for advanced disease; Transfer of any part; If any tumor >T4a (accompanied by skin invasion, mass adhesion fixation, inflammatory breast cancer); Patients with clinical or imaging suspicion of malignancy on the opposite breast but not confirmed, requiring biopsy; Have received neoadjuvant therapy, including chemotherapy, radiotherapy and endocrine therapy; Malignant neoplasms (other than basal cell carcinoma of the skin and carcinoma in situ of the cervix), including contralateral breast cancer, within the previous 5 years; The patient has been enrolled in other clinical trials; Patients with severe systemic disease and/or uncontrolled infection were unable to be enrolled in the study; LVEF<50% (cardiac ultrasound); Severe cardiovascular and cerebrovascular disease (e.g., unstable angina, chronic heart failure, uncontrolled hypertension >150/90mmgh, myocardial infarction or cerebrovascular accident) within 6 months prior to randomization; Known allergy to related drugs; Women of childbearing age refuse contraception during treatment and within 8 weeks after completion of treatment; Pregnant and lactating women; Those who tested positive for pregnancy before taking the drug after joining the trial; Mental illness, cognitive impairment, inability to understand the trial protocol and side effects, inability to complete the trial protocol and follow-up workers ;(systematic evaluation is required before trial enrollment); Persons without personal freedom and independent capacity for civil conduct。
引自 ClinicalTrials.gov, NCT05883852, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05883852,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。